Clinical Trial Update: A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH) [Phase 2]

View source ↗

Summary

A Phase 2 study of IkT-001Pro for pulmonary arterial hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• IkT-001Pro

Snippet

Sponsor: Inhibikase Therapeutics | Conditions: Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Phase 2 | Status: WITHDRAWN